Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR2 | P21802 | 8/20 | 0.47 |
| ▸ | FGFR3 | P22607 | 7/20 | 0.47 |
| ▸ | MET | P08581 | 9/20 | 0.46 |
| ▸ | KDR | P35968 | 4/20 | 0.45 |
| ▸ | FGFR4 | P22455 | 6/20 | 0.42 |
| ▸ | FGFR1 | P11362 | 5/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.41 |
| ▸ | YES1 | P07947 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3258189 | 0.84 | MET (0.50) | FGFR2FGFR3METKDRFGFR4 | |
| SCHEMBL20808254 | 0.80 | FGFR2 (0.47) | FGFR2FGFR3METKDRFGFR4 | |
| SCHEMBL14905436 | 0.79 | FGFR2 (0.59) | FGFR2FGFR3KDRFGFR4FGFR1 | |
| SCHEMBL15507752 | 0.75 | TTK (0.47) | MET | |
| SCHEMBL15886100 | 0.71 | FGFR3 (0.46) | FGFR2FGFR3METKDRFGFR4 | |
| SCHEMBL20951235 | 0.71 | FGFR3 (0.52) | FGFR2FGFR3METKDRFGFR4 | |
| SCHEMBL15884794 | 0.70 | MET (0.38) | METMAPK1AURKB | |
| SCHEMBL17035999 | 0.70 | FGFR2 (0.67) | FGFR2FGFR3METKDRFGFR4 | |
| SCHEMBL20946505 | 0.69 | GSK3B (0.55) | FGFR2FGFR3KDRMAPK1AURKB | |
| SCHEMBL17038912 | 0.69 | FGFR2 (0.69) | FGFR2FGFR3METKDRFGFR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2861584-B1 | Pyridopyrazine and naphthyridine derivatives for the treatment of cancer | ASTEX THERAPEUTICS LTD (GB) | 2020-02-19 | — | — | EP | disclosed |
| EP-2776436-B1 | NEW COMPOUNDS | ASTEX THERAPEUTICS LTD (GB) | 2019-03-13 | — | — | EP | disclosed |
| US-9757364-B2 | Naphthyridine derivative compounds | ASTEX THERAPEUTICS LTD (GB) | 2017-09-12 | — | — | US | disclosed |
| US-9757364-B2 | Naphthyridine derivative compounds | ASTEX THERAPEUTICS LTD (GB) | 2017-09-12 | — | — | US | disclosed |
| US-9737544-B2 | Compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2017-08-22 | — | — | US | disclosed |
| US-9737544-B2 | Compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2017-08-22 | — | — | US | disclosed |
| US-20170105978-A1 | NEW COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2017-04-20 | — | — | US | disclosed |
| US-20170105978-A1 | NEW COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2017-04-20 | — | — | US | disclosed |
| US-9527844-B2 | Naphthyridine derivative compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2016-12-27 | — | — | US | disclosed |
| US-9527844-B2 | Naphthyridine derivative compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2016-12-27 | — | — | US | disclosed |
| US-20160108034-A1 | NAPHTHYRIDINE DERIVATIVE COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2016-04-21 | — | — | US | disclosed |
| US-9309241-B2 | Naphthyridine derivative compounds | ASTEX THERAPEUTICS LTD (GB) | 2016-04-12 | — | — | US | disclosed |
| US-9309241-B2 | Naphthyridine derivative compounds | ASTEX THERAPEUTICS LTD (GB) | 2016-04-12 | — | — | US | disclosed |
| US-9303030-B2 | Compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2016-04-05 | — | — | US | disclosed |
| US-9303030-B2 | Compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2016-04-05 | — | — | US | disclosed |
| US-20150239883-A1 | NEW COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2015-08-27 | — | — | US | disclosed |
| US-20150239883-A1 | NEW COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2015-08-27 | — | — | US | disclosed |
| US-20150057293-A1 | NEW COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2015-02-26 | — | — | US | disclosed |
| US-20150057293-A1 | NEW COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2015-02-26 | — | — | US | disclosed |
| WO-2013061077-A1 | NEW COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2013-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150057293-A1 | NEW COMPOUNDS | NQO1, NTPCR, NDC1 | FGFR2 2426/4885FGFR3 2292/4885MET 3578/4885 |
| US-20170105978-A1 | NEW COMPOUNDS | NQO1, NTPCR, NDC1 | FGFR2 2426/4885FGFR3 2292/4885MET 3578/4885 |
| US-20160108034-A1 | NAPHTHYRIDINE DERIVATIVE COMPOUNDS | NQO1, NDC1, NTPCR | FGFR2 1858/4885FGFR3 2257/4885MET 3261/4885 |
| US-20150239883-A1 | NEW COMPOUNDS | NTPCR, MT-ND5, NQO1 | FGFR2 2213/4885FGFR3 2473/4885MET 3487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.